Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68


HLA-B molecules target more conserved regions of the HIV-1 proteome.

Fontaine Costa AI, Rao X, Lechenadec E, van Baarle D, Keşmir C.

AIDS. 2010 Jan 16;24(2):211-5. doi: 10.1097/QAD.0b013e328334442e.


HIV/AIDS. HLA leaves its footprints on HIV.

McMichael A, Klenerman P.

Science. 2002 May 24;296(5572):1410-1. No abstract available.


Selection of escape mutation by Pol154-162-specific cytotoxic T cells among chronically HIV-1-infected HLA-B*5401-positive individuals.

Hashimoto M, Kitano M, Honda K, Koizumi H, Dohki S, Oka S, Takiguchi M.

Hum Immunol. 2010 Feb;71(2):123-7. doi: 10.1016/j.humimm.2009.10.015.


Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.

Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ, Walker BD.

AIDS. 2003 Dec 5;17(18):2581-91.


HIV-1-specific cytotoxic T lymphocyte (CTL) responses against immunodominant optimal epitopes slow the progression of AIDS in China.

Zhai S, Zhuang Y, Song Y, Li S, Huang D, Kang W, Li X, Liao Q, Liu Y, Zhao Z, Lu Y, Sun Y.

Curr HIV Res. 2008 Jun;6(4):335-50.


Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses.

Gaudieri S, Nolan D, McKinnon E, Witt CS, Mallal S, Christiansen FT.

Mol Immunol. 2005 Feb;42(4):557-60. Review.


Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57.

Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ, Kiama P, Peto T, Plummer FA, McMichael AJ, Rowland-Jones SL.

AIDS. 2002 May 3;16(7):961-72.


The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, Ehler L, Metcalf J, Liu S, Hallahan CW, Connors M.

J Virol. 2003 Jun;77(12):6889-98.


Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses.

Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K, Woodberry T, Sango K, Hewitt HS, Henry L, Linde CH, Chisholm JV 3rd, Zaman TM, Pae E, Mallal S, Walker BD, Sette A, Korber BT, Heckerman D, Brander C.

J Immunol. 2006 Apr 1;176(7):4094-101.


Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.

Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, Seoighe C, Treurnicht F, de Rosa DA, Hide W, Karim SA, Gray CM, Williamson C; CAPRISA 002 Study Team..

PLoS Pathog. 2008 Mar 21;4(3):e1000033. doi: 10.1371/journal.ppat.1000033.


Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ.

Nature. 2004 Dec 9;432(7018):769-75.


A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef.

Navis M, Schellens IM, van Swieten P, Borghans JA, Miedema F, Kootstra NA, van Baarle D, Schuitemaker H.

J Infect Dis. 2008 Mar 15;197(6):871-9. doi: 10.1086/528695.


Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.

Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA.

Science. 2002 May 24;296(5572):1439-43.


Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.

Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, Ryvkin F, Derdeyn CA, Allen S, Hunter E, Mulenga J, Goepfert PA, Walker BD, Allen TM.

J Virol. 2007 Nov;81(22):12608-18.


Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes.

Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, Pae E, Wurcel AG, Roach T, St John MA, Altfeld M, Marincola FM, Moore C, Mallal S, Carrington M, Heckerman D, Allen TM, Mullins JI, Korber BT, Goulder PJ, Walker BD, Brander C.

Nat Immunol. 2006 Feb;7(2):173-8.


Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection.

Goulder PJ, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B, Edwards A, Giangrande P, Phillips RE, McMichael AJ.

AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8.


An unanticipated lack of consensus cytotoxic T lymphocyte epitopes in HIV-1 databases: the contribution of prediction programs.

Schellens IM, Keşmir C, Miedema F, van Baarle D, Borghans JA.

AIDS. 2008 Jan 2;22(1):33-7.


Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Geels MJ, Dubey SA, Anderson K, Baan E, Bakker M, Pollakis G, Paxton WA, Shiver JW, Goudsmit J.

J Virol. 2005 Sep;79(17):11247-58.


Differential characteristics of cytotoxic T lymphocytes restricted by the protective HLA alleles B*27 and B*57 in HIV-1 infection.

Schellens IM, Spits HB, Navis M, Westerlaken GH, Nanlohy NM, Coffeng LE, Kootstra N, Miedema F, Schuitemaker H, Borghans JA, van Baarle D.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):236-45. doi: 10.1097/QAI.0000000000000324.


Identification and characterization of 2 HIV-1 Gag immunodominant epitopes restricted by Asian HLA allele HLA-B*4801.

Murakoshi H, Kitano M, Akahoshi T, Kawashima Y, Dohki S, Oka S, Takiguchi M.

Hum Immunol. 2009 Mar;70(3):170-4. doi: 10.1016/j.humimm.2008.12.011.


Supplemental Content

Support Center